Pooled Analyses of Anatomic and Visual Function Data of Revakinagene Taroretcel-lwey in Participants with Macular Telangiectasia Type 2
Year: 2026
Type: article
Abstract: PURPOSE: To assess anatomic and visual function data from 3 randomized, sham-controlled clinical trials of revakinagene taroretcel-lwey in participants with macular telangiectasia type 2 (MacTel). DESIGN: This study pooled data from 1 phase II (NTMT-02) clinical trial and 2 identically designed phase III (NTMT-03-A and NTMT-03-B) clinical trials of revakinagene taroretcel-lwey in MacTel. PARTICIPANTS: In total, 67 participants (99 eyes) from NTMT-02, 115 participants (115 eyes) from NTMT-03-A, and 113 participants (113 eyes) from NTMT-03-B were included in the study. The pooled population included 327 eyes from 295 participants (165 participants who received revakinagene taroretcel-lwey and 162 who underwent sham surgical procedure). METHODS: Assessments were conducted on data from the individual trials as well as on a single pooled population from all 3 trials. MAIN OUTCOME MEASURES: The rate of ellipsoid zone (EZ) area loss over 24 months and changes from baseline in monocular reading speed loss, aggregate retinal sensitivity loss measured by microperimetry, and best-corrected visual acuity (BCVA) were assessed. RESULTS: /24 months; 95% CI, 0.154-0.217) (nominal P = 0.003). A 68.2% reduction in monocular reading speed loss at 24 months from baseline was observed with revakinagene taroretcel-lwey (-4.65 words per minute [WPM]; 95% CI, -9.58 to -0.27) versus sham (-14.60 WPM; 95% CI, -20.41 to -8.79) (nominal P = 0.01). Across the 3 trials, a 36.6% reduction in aggregate retinal sensitivity loss was reported over 24 months with revakinagene taroretcel-lwey (28.47 dB; 95% CI, 6.62-50.31) compared with sham (44.85 dB; 95% CI, 36.99-52.72) (nominal P < 0.001). Both treatment groups experienced minimal changes in BCVA over 24 months. CONCLUSIONS: In this pooled analysis, revakinagene taroretcel-lwey reduced the rate of MacTel disease progression and preserved visual function over 24 months, as shown by reductions in the rate of EZ area loss, reading speed loss, and aggregate retinal sensitivity loss. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Source: Ophthalmology Retina
Authors: Roger A. Goldberg, Debora C. Manning, Joanna Yankey, W. Lloyd Clark, Muna I. Bitar, Emily Y. Chew, Martin Friedlander, Arshad M. Khanani, Glenn J. Jaffe, Eleonora M. Lad, Thomas M. Aaberg, Ian Jeffrey Constable, Chandrakumar Balaratnasingam, Fred Chen, Alain Gaudric, Benedicte Dupas, Ali Erginay, Corinne Guerin, Aude Jacob, Valerie Krivosic, Valerie Mane-Tauty, Julie Smati, Catherine Egan, Odysseas Georgiadis, James Bainbridge, Edward Bloch, Lyndon da Cruz, Simona Esposti, Blanca Flores Sanchez, Tjebo Heeren, Yanling Ouyang, Filipa Rodrigues, Taha Soomro, Sandra Vermeirsch, Peter Charbel-Issa, Robert MacLaren, Steven D. Schwartz, Jean-Pierre Hubschman, Greg Budoff, Ismael Chehaibou, Alexander Dillon, Anibal Francone, Wei Gui, Samuel Hobbs, Hamid Hosseini, Kirk Hou, Jason Huang, Nicholas Iafe, Nikisha Kothari
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,920
OpenAlex ID: W7169753690
